Logo

People in the News: Mark Kowalski, Ian Mortimer, Jeffrey Jonas

Aug 15, 2013
Premium

Tekmira Pharmaceuticals has appointed Mark Kowalski as its chief medical officer.

Before joining Tekmira, he was chief medical officer of YM BioSciences. He joined Gilead Sciences following its acquisition of YM.

Tekmira also disclosed that its CFO Ian Mortimer will leave the company Oct. 15. He has been with Tekmira for five years.

The search for a new CFO is underway.

Sage Therapeutics has named Jeffrey Jonas as its new CEO.

Jonas previously served as executive vice president of Isis Pharmaceuticals.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Drug Discovery & Development
Tekmira
Isis
RNAi
antisense
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.